Citius Pharmaceuticals, Inc.
General ticker "CTXR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $14.1M (TTM average)
Citius Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -15.8%.
Estimated limits based on current volatility of 6.0%: low 0.60$, high 0.67$
Factors to consider:
- Total employees count: 22 as of 2023
- Top business risk factors: Net losses, Fundraising challenges, Regulatory and compliance, Operational and conduct risks, Acquisition/divestiture risks
- Current price 38.1% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-09-30 to 2027-09-30
- 2025-09-30 to 2026-09-30 estimated range: [0.94$, 3.24$]
- 2026-09-30 to 2027-09-30 estimated range: [1.02$, 3.32$]
Financial Metrics affecting the CTXR estimates:
- Positive: with PPE of -0.3 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Inventory ratio change, % of 0 <= 0.78
- Positive: 42.59 < Shareholder equity ratio, % of 51.59 <= 64.29
- Positive: Interest expense per share per price, % of 2.06 <= 3.31
Short-term CTXR quotes
Long-term CTXR plot with estimates
Financial data
| YTD | 2023-09-30 | 2024-09-30 | 2025-09-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $36.73MM | $42.00MM | $38.53MM |
| Operating Income | $-36.73MM | $-42.00MM | $-38.53MM |
| Non-Operating Income | $4.77MM | $3.15MM | $-0.16MM |
| Interest Expense | $0.00MM | $0.00MM | $0.27MM |
| R&D Expense | $14.82MM | $11.91MM | $9.16MM |
| Income(Loss) | $-31.97MM | $-38.85MM | $-38.68MM |
| Taxes | $0.58MM | $0.58MM | $-1.06MM |
| Net Income(Loss)* | $-32.54MM | $-39.14MM | $-37.43MM |
| Stockholders Equity | $90.83MM | $70.08MM | $67.55MM |
| Inventory | $0.00MM | $8.27MM | $22.29MM |
| Assets | $103.61MM | $116.65MM | $130.94MM |
| Operating Cash Flow | $-29.06MM | $-28.20MM | $-26.55MM |
| Investing Cash Flow | $0.00MM | $-5.00MM | $-5.75MM |
| Financing Cash Flow | $13.83MM | $9.97MM | $33.30MM |
| Earnings Per Share** | $-3.34 | $-3.38 | $-3.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.